UCB (STU:UNC) Treasury Stock: €-334 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:UNC UCB SA STU:UNC
91 GF Score
Price €220.20
GF Value €250.71
Valuation Modestly Undervalued
View Full Analysis

What is UCB Treasury Stock?

UCB STU:UNC -1.52% 91 Treasury Stock is €-334 Mil as of Jun. 2026. GuruFocus rates STU:UNC with a GF Score™ of 91/100 and a GF Value™ of €250.71 (Modestly Undervalued).

Treasury stock is the portion of shares that a company keeps in their own treasury. UCB's treasury stock for the quarter that ended in Jun. 2026 was €-334 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

UCB Treasury Stock Historical Data

* Premium members only.

The historical data trend for UCB's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UCB Treasury Stock Chart

UCB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Treasury Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only -395.00 -363.00 -353.00 -384.00 -389.00

UCB Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -409.00 -384.00 -419.00 -389.00 -334.00
STU:UNC
91GF Score
UCB SA STU:UNC
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UCB Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of €-334 Mil mean?
UCB (STU:UNC) has a Treasury Stock of €-334 Mil as of Jun. 2026. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for UCB and its competitors.
Is UCB's Treasury Stock too high?
UCB's current Treasury Stock is €-334 Mil. Overall, UCB has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does UCB's Treasury Stock compare to VRTX and REGN?
UCB's Treasury Stock of €-334 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for UCB and its competitors. UCB's current Treasury Stock is €-334 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (STU:UNC) is currently considered Modestly Undervalued. The stock's GF Value™ is €250.71, compared to a current price of €220.20 — trading 12.2% below its estimated fair value. The current Treasury Stock is €-334 Mil. UCB's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For UCB (STU:UNC), the current Treasury Stock is €-334 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UCB (STU:UNC) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be undervalued. The current stock price of €220.20 is trading 12.2% below its estimated GF Value™ of €250.71. GuruFocus considers UCB to be Modestly Undervalued.

Key valuation signals for STU:UNC:

  • Treasury Stock: €-334 Mil
  • GF Value™: €250.71 vs. price of €220.20 (12.2% below fair value)
  • GF Score™: 91/100

No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
91GF Score

Get the complete analysis for STU:UNC

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€220.20
Price
€250.71
GF Value